TRIAL INFORMATION
Sponsor:ApexCardio Pharmaceuticals
Therapeutic Area:Cardiology
Phase:PHASE II
Indication:Atrial Fibrillation
Target Enrollment:60 patients
Est. Duration:24 months
SITE INFORMATION
Site:MedPoint Clinical Research - Nashville
Principal Investigator:Dr. Sarah Chen, MD, PhD
Total FTE Capacity:12
Available FTE:1.8
Active Trials:6
Completed Trials:18
Pool Analysis
FTE Analysis
Financial
Risk Assessment
Recommendation
Patient Pool Adequacy Analysis
Assessing whether the available patient pool can support target enrollment
A pool adequacy ratio of 2.5x or higher indicates comfortable capacity for successful enrollment.
TOTAL POOL
3,200
AVAILABLE
2,620
580 allocated
REQUIRED
60
ADEQUACY RATIO
43.7x
Pool Utilization
Current Allocation18.1%
If This Trial Accepted20.0%
Pool is Sufficient
Available pool is 43.7x the target enrollment, providing a comfortable buffer for recruitment.
Pool Adequacy Score100 / 100